 LAVAL, Quebec--BUSINESS WIRE--BELLUS Health Inc. Nasdaq:BLU; TSX:BLU BELLUS Health or the Company, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Companys highly selective P2X3 antagonist, in patients with refractory chronic cough 